Ra223 in bone metastases with osteolytic activity

Ra223 in bone metastases with osteolytic activity

Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast c...

Full description

Bibliographic Details
Main Authors: Renato Patrizio Costa, Davide Cardile, Alessandra Murabito, Vincenzo Tripoli, Francesco Verderame
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:World Journal of Nuclear Medicine
Subjects:
Bone metastases
breast cancer
osteoblastic bone metastases
osteolytic bone metastases
radium 223
Online Access:http://www.wjnm.org/article.asp?issn=1450-1147;year=2018;volume=17;issue=2;spage=116;epage=119;aulast=Costa

Internet

http://www.wjnm.org/article.asp?issn=1450-1147;year=2018;volume=17;issue=2;spage=116;epage=119;aulast=Costa

Similar Items